1 李玮, 王欢, 王延江, 等. 完善卒中绿色通道对提高急性缺血性卒中静脉溶栓率的影响[J]. 重庆医学, 2014,43:1979-1982.2 重组组织型纤溶酶原激活剂治疗缺血性卒中共识专家组. 重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识(2012版)[J]. 中华内科杂志, 2012,51:1006-1010.3 Marler JR, Tilley BC, Lu M, et al. Early stroketreatment associated with better outcome: the NINDSrt-PA stroke study[J]. Neurology, 2000, 55:1649-1655.4 Fonarow GC, Smith EE, Saver JL, et al. Timelinessof tissue type plasminogen activator therapy in acuteischemic stroke: patient characteristics, hospitalfactors, and outcomes associated with door to needletimes within 60 minutes[J]. circulation, 2011, 123:750-758.5 Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines forthe early management of patients with acute ischemicstroke: a guideline for healthcare professionals fromthe American Heart Association/American StrokeAssociation[J]. Stroke, 2013, 44:870-947.6 Reeves MJ, Fonarow GC, Zhao X, et al. Get WithThe Guidelines-Stroke Steering Committee &Investigators. Quality of care in women with ischemicstroke in the GWTG program[J]. Stroke, 2009,40:1127-1133.7 Fonarow GC, Smith EE, Saver JL, et al. Timelinessof tissue-type plasminogen activator therapy in acuteischemic stroke: patient characteristics, hospitalfactors, and outcomes associated with door-to-needle times within 60 minutes[J]. Circulation, 2011,123:750-758. |